Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients whose legal representatives can provide informed consent (Informed consent from the patients where possible).~* Patients who satisfy both of the following diagnostic criteria:~  * Diagnosis of major neurocognitive disorder due to Alzheimer's disease according to Diagnostic and Statistical Manual of mental disorders (DSM-5)~ * Diagnosis of probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)~* Hospitalized patients or care facility patients~* Patients with an Mini-Mental State Examination (MMSE) score of 1 to 22~Exclusion Criteria:~* Patients with complications of dementia or memory impairment other than Alzheimer's type dementia~* Dementia patients with a Modified Hachinski Ischemic Score of 5 or higher~* Patients with psychological symptoms or behavioral disorders that are clearly due to other medical conditions or substances~* Patients with a complication or history of stroke or transient ischemic attack, except for asymptomatic stroke~* Patients with heart failure classified as New York Heart Asscoiation (NYHA） III or IV~* Patients who require drug therapy for arrhythmia or ischemic heart disease~* Body weight of less than 30 kg~* Patients with a high risk of suicide~* Patients with a complication or history of seizure disorder~* Patients with a complication or history of neuroleptic malignant syndrome, tardive dyskinesia, paralytic ileus, or rhabdomyolysis~* Patients with thyroid disease (except if the disease has been stabilized with drug therapy for 3 months or longer prior to time of informed consent)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole, 2 mg/day (Type: EXPERIMENTAL): None
- Aripiprazole, 3 mg/day (Type: EXPERIMENTAL): None
- Aripiprazole, 6 mg/day (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).